Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfredo Addeo

Showing results (191-200 of 224) with videos related to

Pageof 23
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 29, 2020
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%Giulio Metro, Giuseppe Luigi Banna, Diego Signorelli, et al.
Cancer Cell|July 2, 2021
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancerAlfredo Addeo, Pankil K Shah, Natacha Bordry, et al.
Clinical Lung Cancer|November 9, 2020
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab MonotherapyGiannis Mountzios, Alessandro de Toma, Panagiota Economopoulou, et al.
Expert Review of Molecular Diagnostics|September 27, 2021
Liquid biopsy from research to clinical practice: focus on non-small cell lung cancerUmberto Malapelle, Pasquale Pisapia, Alfredo Addeo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Jair Bar, Nir Peled, Shiruyeh Schokrpur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Future Oncology (London, England)|November 27, 2023
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summaryGrace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 1, 2021
Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape ProjectStephen P Finn, Alfredo Addeo, Urania Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2025
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trialMatthias Guckenberger, Isabelle Opitz, Tereza Dellaporta, et al.
Therapeutic Advances in Medical Oncology|June 20, 2022
Real-world experience with capmatinib in <i>MET</i> exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access programOliver Illini, Hannah Fabikan, Aurélie Swalduz, et al.
Pageof 23

Showing results (191-200 of 224) with videos related to

Sort By:
Pageof 23
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 29, 2020
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%Giulio Metro, Giuseppe Luigi Banna, Diego Signorelli, et al.
Cancer Cell|July 2, 2021
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancerAlfredo Addeo, Pankil K Shah, Natacha Bordry, et al.
Clinical Lung Cancer|November 9, 2020
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab MonotherapyGiannis Mountzios, Alessandro de Toma, Panagiota Economopoulou, et al.
Expert Review of Molecular Diagnostics|September 27, 2021
Liquid biopsy from research to clinical practice: focus on non-small cell lung cancerUmberto Malapelle, Pasquale Pisapia, Alfredo Addeo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Jair Bar, Nir Peled, Shiruyeh Schokrpur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Future Oncology (London, England)|November 27, 2023
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summaryGrace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 1, 2021
Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape ProjectStephen P Finn, Alfredo Addeo, Urania Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2025
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trialMatthias Guckenberger, Isabelle Opitz, Tereza Dellaporta, et al.
Therapeutic Advances in Medical Oncology|June 20, 2022
Real-world experience with capmatinib in <i>MET</i> exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access programOliver Illini, Hannah Fabikan, Aurélie Swalduz, et al.
Pageof 23